Aphios Corporation

Aphios Awarded NIH Grant for CFI Virus and Pathogen Inactivation Technology for Blood Products and Biologics

Published in Blood Weekly, August 20th, 2009

Aphios Corporation announced that it has been awarded a Phase I Small Business Innovative Research (SBIR) grant from the National Heart Lung and Blood Institute (NHLBI), National Institutes of Health (NIH) to develop CFI as a generally-applicable virus and pathogen inactivation technology for human plasma, plasma products and biologics.

The recent outbreaks of potentially pandemic strains of influenza such as the H1N1 swine flu and the H5N1 bird flu, the worldwide AIDS epidemic, the emergence of West Nile virus and Babesia spp, and the periodic emergence of Ebola and SARS as well as the bioterrorism potential have highlighted a persistent concern in the health care...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2009-08-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry